The aim of this report was to assess the added benefit of canagliflozin for the treatment of adult patients with type 2 diabetes mellitus in comparison with the appropriate comparator therapy (ACT) in the following approved subindications:
http://ift.tt/2sen02c
Πέμπτη 15 Ιουνίου 2017
Canagliflozin -- Benefit Assessment According to §35a Social Code Book V [Internet].
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Summary Insulinomas are rare neuroendocrine tumours that classically present with fasting hypoglycaemia. This case report discusses an un...
-
The online platform for Taylor & Francis Online content New for Canadian Journal of Remote Sen...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου